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A B S T R A C T
The current study presents a safety evaluation of a novel glucuronoxylan hydrolase (EC 3.2.1.136) from Bacillus
subtilis produced in Bacillus licheniformis. The glucuronoxylan hydrolase preparation did not exhibit irritative
potential to the eye and skin when applied in in vitro models. The glucuronoxylan hydrolase preparation was
non-mutagenic and non-clastogenic in in vitro tests. Oral administration of the glucuronoxylan hydrolase pre-
paration to rats did not cause any adverse eﬀect in a 90-days subchronic toxicity study. A tolerance study was
performed with broiler chickens and conﬁrmed that this glucuronoxylan hydrolase is safe for broiler chickens
when fed at the maximum recommended dose, as well as at the 10 times higher dose.
In conclusion, there are no safety concerns with using this novel glucuronoxylan hydrolase as a feed additive
as it is toxicologically inert and the glucuronoxylan hydrolase is well tolerated by broiler chickens. The beneﬁcial
safety evaluation of glucuronoxylan hydrolase is consistent with the fact that this type of enzyme is ubiquitous in
nature.
1. Introduction
The structural carbohydrates of the plant cell wall are an important
energy source for animals, but the energy is not easily accessible for
mammals and birds which do not produce all the necessary enzymes to
break down the cell wall (Ravn et al., 2016). Adding enzymes to animal
feed to help increase nutrient digestibility and optimize nutritional
value of the diet is a common practice in modern feed formulation
(Adeola and Cowieson, 2011). A wide range of enzymes is available to
optimize nutrient utilization from feed ingredients; e.g. the use of
phytases, glucanases, xylanases, hemi-cellulases and proteases (Adeola
and Cowieson, 2011; Dersjant-Li et al., 2015; Cowieson and Roos,
2016) enhances the bioavailability of nutrients for the animal and/or
for its intestinal microbiota (Józeﬁak et al., 2010; Bedford and
Cowieson, 2012; Kiarie et al., 2013). Thus, employing enzymes can
optimize the use of feed for eﬃcient production of animal protein
making enzymes essential contributors to the sustainability rating of
meat production (Bundgaard et al., 2014; Leinonen and Kyriazakis,
2016).
To the best of our knowledge, molecules with Enzyme Commission
number 3.2.1.136 (glucuronoarabinoxylan endo-1,4-β-xylanase) have
not previously been used in animal feed. Glucuronoxylan hydrolase
enzymes hydrolyze highly branched arabinoxylan polysaccharides into
small oligomers, thus catalyzing the breakdown of cell walls hemi-
cellulose of cereals like corn, rice and sorghum (Biely et al., 2016). In a
similar fashion, xylanases of the GH10 and GH11 families hydrolyze
linear and lowly substituted beta-1,4-xylan polysaccharides (Ravn
et al., 2016, 2017; Biely et al., 2016). Xylanases have large commercial
usage in the paper and textile industries, and also in food and feed
production (Polizeli et al., 2005). Several bacterial xylanases are com-
mercially available for uses as feed additives (Chakdar et al., 2016).
Xylanases are readily biodegradable and the potential environmental
toxicity of xylanases has been described to be minimal as shown in
toxicity studies with algae, daphnia and ﬁsh as reported in the ECHA
REACH registration dossier for xylanase (REACH Registration number
for Xylanase 01-2120747946-38-0000).
The production host, Bacillus licheniformis, is already used as a
production host for several enzymes currently used in feed (Pariza and
Cook, 2010). The literature shows that Bacillus licheniformis is regarded
as non-pathogenic and non-toxigenic (Pariza and Johnson, 2001; de
Boer AS, 1994). Bacillus licheniformis, and several of the enzymes it
produces, is accepted as a constituent of animal feed (AAFCO OP,
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2018). The European Food Safety Agency (EFSA) considers Bacillus li-
cheniformis to meet the requirements for the qualiﬁed presumption of
safety (QPS) (EFSA, 2007). According to the new guidance from EFSA
“on the assessment of the safety of feed additives for the consumer”
which entered into force on the 1st of May 2018, no studies concerning
the safety of use for the additive for the consumers are required for
enzymes produced by genetically modiﬁed microorganisms for which
the recipient strain is considered by EFSA to qualify for QPS, and for
which the molecular characterization of the event does not give rise to
concern (EFSA, 2017).
The Bacillus licheniformis production strain used in this study derives
from Ca63 (DSM 9552) and is genetically modiﬁed to produce a mod-
iﬁed glucuronoxylan hydrolase from Bacillus subtilis (ATCC 6051).
In the present study, we report the in vivo tolerance test of this novel
glucuronoxylan hydrolase (EC 3.2.1.136) in broiler chickens as pre-
scribed by the European Food Safety Authority (EFSA, 2011).
Further, a series of toxicological studies were carried out to evaluate
the safety of this novel glucuronoxylan hydrolase as suggested by Pariza
and his colleagues (Pariza and Johnson, 2001; Pariza and Cook, 2010)
and corresponding to the safety assessment of enzymes performed by
Lichtenberg and colleagues (Lichtenberg et al., 2011; Lichtenberg et al.,
2017). The toxicological studies presented here comply with the re-
quirements of the European Union Regulation N° 1831/2003 on ad-
ditives for use in animal nutrition and its corresponding guidelines
(EFSA, 2012). Speciﬁcally, the enzyme preparation was subjected to a
neutral red uptake cytotoxicity test in 3T3 cells, an in vitro eye irrita-
tion/corrosion study in chicken eyes, an in vitro skin irritation test using
EpiDerm human reconstituted skin membranes, a bacterial reverse
mutation assay, an in vivo micronucleus test and a subchronic oral
toxicity study in rats. The objective of these studies was to demonstrate
the safety of the glucuronoxylan hydrolase as a feed additive compiling
the safety information on the production strain, and the results of a
relevant toxicological studies as well as a target animal tolerance study
in broiler chickens, as prescribed by the European Food Safety Au-
thority (EFSA, 2011).
2. Materials and methods
2.1. Construction of the production strain
The wild type glucuronoxylan hydrolase gene is from Bacillus subtilis
(ATCC 6051). The DNA sequence of the wild type gene was modiﬁed to
change 5 amino acids to create the glucuronoxylan hydrolase product.
The construct was cloned into E. coli using standard vectors with strictly
deﬁned and well-characterised DNA sequences that are known not to
encode or express any harmful or toxic substances, to create a plasmid
containing the glucuronoxylan hydrolase expression cassette. The glu-
curonoxylan hydrolase expression cassette was introduced through re-
combination into the Bacillus licheniformis recipient strain derived from
Ca63 (DSM 9552) using a standard transformation procedure. The
transformants were subsequently evaluated by gene sequencing to as-
sess incorporation of the expression cassette and to ensure that no un-
intended sequences were incorporated into the genome of the selected
production strain. The glucuronoxylan hydrolase protein expressed
from the introduced genes in the ﬁnal production strain was veriﬁed by
mass spectroscopy to be 100% identical to the protein sequence en-
coded by the donor gene.
2.2. Preparation of the glucuronoxylan hydrolase test substance
The glucuronoxylan hydrolase preparation evaluated in the present
study was carried out in an industrial pilot biotechnological set-up
certiﬁed according to ISO 9001 and in accordance with the procedures
used for the manufacturing of commercial enzyme products. In brief,
the genetically modiﬁed Bacillus licheniformis production strain de-
scribed in Section 2.1, was cultivated in a bioreactor using a medium
made of sterilized food-grade ingredients with pH adjustment. At the
end of the process, the product was separated from the production or-
ganism using a series of ﬁltration and concentration steps. Finally, a
series of chemical and microbial analysis were carried out to char-
acterize the glucuronoxylan hydrolase preparation. The liquid fermen-
tation broth was used for the toxicological studies. A dried solid form of
the product was produced by granulation following well-established
industrial production practices and was used in a tolerance study with
broiler chickens.
2.3. Characterization of the glucuronoxylan hydrolase test substance
Glucuronoxylan hydrolase activity is expressed in glucuronoxylan
hydrolase units (GXH(A)). One GXH(A) is deﬁned as the amount of
enzyme required to liberate 7.55 nmole of reducing sugar measured as
xylose equivalents per minute at 50 °C and pH 5.0. The glucuronoxylan
hydrolase preparation was also analyzed for chemical and microbial
status using standard methods (Table 1). Total organic solids (TOS)
from the fermentation consists mainly of protein and carbohydrate
components and was calculated as follows: TOS (%)= 100 - water (%) -
ash (%). The TOS content of glucuronoxylan hydrolase was 8.5% (w/
w).
The enzyme activity was 42944 GXH(A)/g for the toxicological
studies. For the tolerance study in broiler chickens, the glucuronoxylan
hydrolase was evaluated at a maximum recommended dose (11666
GXH(A)/kg diet) and a ten times overdose (116658 GXH(A)/kg diet)
when added to standard starter, grower and ﬁnisher diets for a period of
6 weeks as described in 2.4.7.
2.4. Toxicological evaluation of glucuronoxylan hydrolase
The toxicological studies were performed in accordance with the
current OECD guidelines and with Good Laboratory Practice (OECD,
1998a). The in vivo studies were performed in agreement with the
regulations and ethical guidelines on the use of animals for experi-
mental purposes of the local authorities of the countries where the
studies were performed.
2.4.1. Subchronic oral toxicity in rat
A 13-week subchronic toxicity study in rats was conducted.
Glucuronoxylan hydrolase was administered by oral gavage to assess
the toxic potential of the enzyme. The study was carried out by Envigo
Table 1
Composition analyzes of the glucuronoxylan hydrolase preparation for the
toxicological studies. ND=not detected.
Composition analyzes of glucuronoxylan hydrolase for toxicological studies.
Composition analyzes
Enzyme activity GXH(A)/g 42944
Carbohydrate (anthron) (g/kg) 10.3
Carbohydrate (tryptophan) (g/kg) 15.4
Water (Karl Fisher) (% w/w) 89.1
Total Organic Solids (% w/w) 8.5
Dry Matter (% w/w) 10.9
Ash (% w/w) 2.4
N-total (% w/w) 0.92
Pb (ppm) <0.5
As (ppm) <0.3
Cd (ppm) <0.05
Hg (ppm) <0.05
Cu (ppm) 0.57
Total viable count CFU/g <100
Salmonella CFU/25 g ND
Coliform bacteria CFU/g <4
Enteropathogenic E. coli CFU/25 g ND
Sulphur-reducing clostridia CFU//g <10
Staphylococcus aureus CFU/g ND
Bacillus licheniformis (Production strain detection) ND
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(Cambridgeshire, UK) following OECD guideline No. 408 (OECD,
1998b). Four groups of Wistar (RccHan™; WIST) rats obtained from
Envigo RMS Ltd. each comprising ten males and ten females, received
glucuronoxylan hydrolase at doses of 0.0, 1.0, 3.3 or 10.0 mL/kg body
weight/day by daily oral gavage administration for 13 weeks. These
doses were equivalent to 88.9, 293 and 889mg TOS/kg body weight/
day and 44880, 148167 or 449265 GXH(A)/kg body weight/day. A
control group received reverse osmosis water (the vehicle) in the same
volume-dose (10mL/kg BW). The rats were 43–49 days old at com-
mencement of treatment and were fed an expanded rodent diet
throughout the study (Teklad 2014C, pelleted diet). Potable water was
freely available via polycarbonate bottles ﬁtted with sipper tubes. The
animals were housed ﬁve of the same gender in each cage. Each animal
was identiﬁed uniquely by microchip. The environment was kept at
temperature within the range 20–24 °C and relative humidity within the
range 40–70%, with a 12-h light and 12-h dark cycle except during
designated procedures. The animals were acclimatized to these condi-
tions for 14 days before treatment commenced. Autoclaved wood
shavings were used as bedding and changed at appropriate intervals.
Aspen chew blocks and plastic shelters were provided as environmental
enrichment in each cage.
It was conﬁrmed by analysis of samples obtained at weeks 1, 6 and
13 that the test formulations were homogeneous and stable at room
temperature (21 °C) for at least 24 h. All formulations were, however,
administered within 4 h of preparation.
Animals received the test substance or vehicle control formulations
orally at a total volume-dose of 10mL/kg body weight, using a suitably
graduated syringe and a rubber catheter inserted via the mouth into the
stomach. Clinical signs were recorded daily. Body weights and food
consumption were recorded once weekly. Water consumption was
monitored daily by visual inspection.
Observations and tests on each animal were performed at the same
time of day on each occasion, and the observer was unaware of the
study group of the animal under assessment. Before treatment com-
menced and weekly during the study each animal was removed from
the home cage and examined for exophthalmos, fur appearance, lacri-
mation, piloerection, reaction to handling, ease of removal from the
home cage, salivation and vocalization on handling. Each animal was
then placed in a standard arena for 1min, during which it was assessed
for arousal, convulsion, gait, grooming, palpebral closure, posture,
tremor, twitches, urination and counts for activity and rearing.
Manipulations, which included assessment of approach response, au-
ditory startle response, tail-pinch response, pupils, righting reﬂex and
touch response and measurement of body temperature, body weight,
grip-strength and landing foot-splay, were performed once before
treatment commenced and again in week 13. Motor activity was mea-
sured before commencement and during week 13 by automated infra-
red sensor equipment that recorded individual animal activity over a 1-
h period.
Ophthalmoscopy was performed on all animals before start of
treatment and at termination on all control rats and those receiving
10.0 mL/kg body weight/day (889mg TOS/kg body weight/day).
Blood samples were taken, after overnight food deprivation, in week
13 using BD Microtainers internally coated with spray-dried K2 EDTA
(BD Cat#365974) and coagulation tubes were prepared at Envigo
(plain polypropylene tubes pre-ﬁlled with sodium citrate at a ratio of 9
parts blood to 1 part citrate). EDTA treated samples were analyzed
using a Bayer Advia 120 Analyzer for a range of hematological para-
meters (hematocrit, hemoglobin concentration, erythrocyte, total and
diﬀerential leucocyte and platelet counts, mean cell volume, mean cell
hemoglobin and mean cell hemoglobin concentration). Derived values
(Hct, MCH and MCHC) were calculated in ClinAxys In ClinAxys the
Rectic gated (g) parameters were used: HCTg = (Retic RBC x Retic
MCV)/1000 and MCHg = (Retic CHCM x Retic MCV)/100. Citrate
treated samples were analyzed for prothrombin and activated partial
thromboplastin times using a Stago STA Compact Max analyzer.
Additional blood samples were obtained at the same time, using BD
Microtainers internally coated with spray-dried lithium heparin, also
containing an inert polymer gel (for plasma separation) (BD
Cat#365985). Using a Roche P Modular Analyzer with an ion-speciﬁc
electrode, the concentrations of glucose, urea, creatinine, total choles-
terol, total proteins, albumin (with calculation of the albumin to glo-
bulin ratio), sodium, and potassium were analyzed in the plasma.
Further, the activities of alkaline phosphatase, alanine and aspartate
amino-transferase and gamma-glutamyl transpeptidase were analyzed
in the plasma.
After completion of the 13-weeks treatment period the rats were
euthanized by carbon dioxide inhalation followed by exsanguination.
They were dissected and examined macroscopically and a range of
tissues collected. Weights were recorded for the adrenals, brain, epi-
didymides, heart, kidneys, liver, ovaries, spleen, testes, thymus and
uterus. Histopathological examination of the following tissues was
performed on the high dose and control animals, adrenals, aorta
(thoracic), brain, caecum, colon, duodenum, epididymides, eyes, femur,
heart, ileum, jejunum, kidneys, liver, lungs, lymph nodes (mandibular
and mesenteric), mammary area, oesophagus, ovaries, pancreas, pitui-
tary, prostate, rectum, salivary glands, sciatic nerve, seminal vesicles,
spinal cord, spleen, sternum, stomach, testes, thymus, thyroid (with
parathyroids), trachea, urinary bladder, uterus (with cervix), and va-
gina. Grossly abnormal tissues were examined for all groups whereas
histopathological examination of the mid- and low-dose groups were
only done if abnormalities were identiﬁed.
A parametric analysis was performed if Bartlett's test for variance
homogeneity (Bartlett, 1937) was not signiﬁcant at the 1% level. The F1
approximate test was applied. This test is designed to detect signiﬁcant
departure from monotonicity of means when the main test for the
comparison of the means is a parametric monotonic trend test, such as
Williams' test (Williams, 1971, 1972). The test statistic compares the
mean square, NMS, for the deviations of the observed means from the
maximum likelihood means, calculated under a constraint of mono-
tonicity with the usual error mean square, EMS. The null hypothesis is
that the true means are monotonically ordered. The test statistic is
F1=NMS/EMS which can be compared with standard tables of the F
distribution with 1 and error degrees of freedom. If the F1 approximate
test for monotonicity of dose-response was not signiﬁcant at the 1%
level, Williams' test for a monotonic trend was applied. If the F1 ap-
proximate test was signiﬁcant, suggesting that the dose response was
not monotone, Dunnett's test (Dunnett, 1955, 1964) was performed
instead. Signiﬁcant diﬀerences between the groups compared were
expressed at the 5% (p < 0.05) or 1% (p < 0.01) level. For organ
weight data, analysis of covariance was performed using terminal body
weight as covariate (Angervall and Carlström, 1963). The treatment
comparisons were made on adjusted group means in order to allow for
diﬀerences in body weight which might inﬂuence the organ weights.
2.4.2. In vitro isolated chicken eye test
Glucuronoxylan hydrolase was evaluated undiluted for eye irrita-
tion potential in the Isolated Chicken Eye (ICE) test in accordance with
OECD guideline 438 (OECD, 2013). The study was carried out at TNO
Triskelion (Zeist, The Netherlands). In addition, the test included a
negative control (saline) and a positive control (BAC 5%). Chicken eyes
were obtained from slaughter animals used for human consumption.
The isolated chicken eyes were exposed to a single application of 30 μL
of the Glucuronoxylan hydrolase test item for 10 s followed by a 20mL
saline rinse. Three main parameters were measured to disclose possible
adverse eye eﬀects: corneal thickness (expressed as corneal swelling),
corneal opacity and ﬂuorescein retention of damaged epithelial cells. In
addition, histopathology of the corneas was performed.
2.4.3. In vitro skin irritation test using EpiDerm™ reconstructed skin
membranes
In vitro skin irritation potential of glucuronoxylan hydrolase was
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assessed using EpiDerm™ reconstructed skin membranes. The study was
conducted in accordance with the OECD guideline 439 (OECD, 2015).
The study was carried out at TNO Triskelion (Zeist, The Netherlands).
2.4.4. Bacterial reverse mutation assay
A bacterial reverse mutation assay (Ames test) was carried out at
Covance (North Yorkshire, England) to assess for mutagenic activity.
The glucuronoxylan hydrolase enzyme preparation may contain free
amino acids, including histidine and tryptophan. This can increase the
apparent number of revertants. To avoid the risk of artefacts due to
growth stimulation, a ‘treat and plate’ protocol was applied (Mahon
et al., 1989; Thompson et al., 2005) as earlier described by Pedersen
and Broadmeadow (2000). The study was conducted in accordance
with the general recommendations in OECD Guideline 471 (1997).
The study utilized four histidine-requiring Salmonella typhimurium
(S. typhimurium) strains and one tryptophan-requiring Escherichia coli
(E. coli) strain capable of detecting induced frame-shift mutations (S.
typhimurium TA1537 and TA98) or base pair substitutions (S. typhi-
murium TA1535, TA100 and E.coli WP2uvrApKM101). Strains TA98,
TA1535 and TA1537 were originally obtained from the UK NCTC.
Strains TA100 and WP2 uvrA pKM101 were derived from cultures
originally obtained from MolTox Inc., USA. The genotypes of the bac-
terial test strains were conﬁrmed as described by Maron and Ames
(1983) and Green (1984). The experiment was conducted twice. Ex-
periment 1 used a broad glucuronoxylan hydrolase concentration range
from 16 to 5000 μg TOS/mL. In experiment 2, a narrowed glucur-
onoxylan hydrolase concentration interval covering the range
160–5000 μg TOS/mL to examine more closely those concentrations of
glucuronoxylan hydrolase, approaching the maximum test concentra-
tion and therefore most likely to provide evidence of mutagenic ac-
tivity. The tests were carried out in the absence and presence of a
metabolic activation system (Mutazyme™ S9 mix from Molecular Tox-
icology Incorporated, USA). In total, four complete and independent
experiments were performed.
For both experiments, the bacterial strains were exposed to all six
concentrations of glucuronoxylan hydrolase, solvent control (sterile
deionized water), and appropriate positive control substances (2-ni-
troﬂuorene, 4-nitroquinoline 1-oxide, N-methyl-N′-nitro- N-ni-
trosoguanidine, ICR-191 mutagen or 2-aminoanthracene, both obtained
from Sigma-Aldrich, UK. See Table 10 for further details) in a phos-
phate buﬀered nutrient broth liquid culture (incubation mixture) in
sterile tubes. The ﬁnal concentrations of glucuronoxylan hydrolase
were 16, 50, 160, 500, 1600 and 5000 μg TOS/mL for experiment 1 and
160, 300, 625, 1250, 2500 and 5000 μg TOS/mL for experiment 2. The
current regulatory guidelines recommend 5000 μg TOS/mL as the
maximum concentration (EFSA, 2014).
Incubation mixtures consisted of 4mL nutrient broth No 2 (Oxoid,
UK), 4 mL of either 0.2M phosphate buﬀer (pH 7.4) (Fisher Scientiﬁc)
or S9 mix, 1 mL bacterial culture, and 1mL glucuronoxylan hydrolase
or control solution. These mixtures were incubated for a period of 3 h at
37 °C. After incubation, test substance and all nutrients originating from
the test substance and broth were removed by centrifuging twice and
washing with phosphate buﬀer. After the last centrifugation, bacterial
cells were re-suspended in 2mL of phosphate buﬀer. Bacteria were
plated out in triplicates on selective agar (Vogel Bonner E agar plates, E
& O Laboratories Ltd) and the number of revertant colonies per plate
was determined as described for the direct plate incorporation assay by
Maron and Ames (1983). Furthermore, the number of viable bacteria in
each culture was determined by plate count. The mean number of re-
vertant colonies per plate and standard deviation were calculated for
each set of replicate plate treatments, and the relative fold increase over
the concurrent vehicle control was calculated for each test article and
positive control mean plate count by dividing this mean value by the
corresponding and concurrent mean vehicle control plate count.
Table 2
Composition of the experimental diets (in %).
Ingredients Starter diet
0–10 days
Grower diet
10–21 days
Finisher diet
21–35 days
Maize 50.29 54.37 59.55
Soybean meal (48% CP) 40.77 36.57 31.54
Soy oil 5.05
Animal fat 5.65 5.68
Dicalcium phosphate 1.98 1.76 1.64
Calcium carbonate 0.66 0.60 0.57
Salt 0.37 0.38 0.38
DL-methionine 0.30 0.20 0.20
L-lysine HCl 0.13 0.02
L-threonine 0.03
Choline chloride 0.03 0.07 0.09
Minerals & vitaminsa 0.30 0.30 0.30
Noxyfeed 0.02 0.02 0.02
Maxiban 0.0625 0.0625
Monteban 0.01
Calculated nutrients
ME, Kcal/kg 3050 3100 3150
Crude protein 22.9 21.0 19.0
Crude ﬁbre 2.3 2.3 2.2
Ether extract 7.3 8.0 8.1
Avail. lysine 1.28 1.06 0.96
Avail. methionine 0.61 0.49 0.47
Avail. methionine + cysteine 0.93 0.79 0.74
Avail. threonine 0.81 0.72 0.65
Avail. tryptophan 0.23 0.21 0.18
Calcium 0.96 0.87 0.81
Total phosphorus 0.68 0.63 0.60
Non-phytate phosphorus 0.48 0.44 0.40
Sodium 0.16 0.16 0.16
a One kg of feed contains: Vitamin A: 12 000 IU; Vitamin D3: 2400 IU;
Vitamin E: 30mg; Vitamin K3: 3 mg; Vitamin B1: 2.2 mg; Vitamin B2: 8mg;
Vitamin B6: 5 mg: Vitamin B12: 11 μg; Folic acid: 1.5 mg; Biotin: 150 μg;
Calcium pantothenate: 25mg; Nicotinic acid: 65mg; Mn: 60mg; Zn: 40mg; I:
0.33mg; Fe: 80mg; Cu: 8mg; Se: 0.15mg; BHT: 25mg.
Table 3
Food intake during 13-week toxicity study in rats. M=males and F= females.
Group/Sex Mean Food Consumption [g/animal/week]
1F Mean 114
SD 4.3
N 2
2F Mean 109
SD 2.8
N 2
% of 1F 96
3F Mean 108
SD 3.6
N 2
% of 1F 95
4F Mean 107
SD 5.2
N 2
% of 1F 94
1M Mean 158
SD 4.9
N 2
2M Mean 151
SD 0.6
N 2
% of 1M 96
3M Mean 149
SD 4.8
N 2
% of 1M 95
4M Mean 147
SD 7.0
N 2
% of 1M 93
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2.4.5. In vitro micronucleus test in cultured human lymphocytes
Glucuronoxylan hydrolase was tested in an in vitro assay using
human lymphocyte cultures prepared from pooled blood from two fe-
male donors. Blood donor details; age: 18–35 years, Selection criteria:
Non-smokers, not heavy drinkers of alcohol, not on any form of medi-
cation (contraceptive pill excluded), not suspected of any virus infec-
tion, or exposed to high levels of radiation or hazardous chemicals. Cell
cycle time: 13 ± 2 h.
The study was conducted according to OECD guideline 487 (OECD,
2016) at Covance Laboratories Ltd. (Harrogate, UK). Treatments –
covering a broad range of concentrations separated by narrow intervals
– were performed both in the absence and presence of metabolic acti-
vation with S9 - an Aroclor-induced rat liver metabolic activation
system (Molecular Toxicology Incorporated, Boone, USA). The test ar-
ticle was formulated in puriﬁed water, and the highest concentration
tested in the Micronucleus Experiment, 5000 μg TOS/mL (an acceptable
maximum concentration for in vitro micronucleus studies according to
current regulatory guidelines), was determined following a preliminary
cytotoxicity Range-Finder Experiment.
Glucuronoxylan hydrolase was added 48 h after mitogen stimula-
tion by phytohaemagglutinin (PHA) (Life Technologies UK). Cells were
exposed to the test article for 3 h in the absence or presence of S9. In
addition, a continuous 24 h treatment (equivalent to approximately
1.5–2 times the average generation time) in the absence of S9 was in-
cluded. The following positive control chemicals were used: cyclopho-
sphamide (CPA) (Acros Organics, Belgium) dissolved in dimethyl
sulphoxide (DMSO) (Sigma–Aldrich, UK), vinblastine (VIN)
(Sigma–Aldrich, UK) and mitomycin C (MMC) (Sigma–Aldrich, UK).
Whole blood cultures were established in tubes by placing 0.4 mL of
pooled heparinised blood into 8.1 mL HEPES-buﬀered RPMI medium
Table 4
13-week toxicity study in rats. Absolute organ weights (g) group mean values for animals killed after 13 weeks of treatment and standard deviation (SD) of males (M)
and females (F).
Terminal body weight Adrenals Brain Epididymides Heart Kidneys Liver Spleen Testes Thymus
1M Mean 412 0.056 2.121 1.332 1.105 2.027 13.710 0.683 3.741 0.360
SD 32 0.008 0.085 0.138 0.201 0.192 1.514 0.073 0.443 0.056
2M Mean 398 0.059 2.097 1.394 1.021 1.995 13.628 0.714 3.780 0.302
SD 32 0.008 0.091 0.122 0.104 0.166 1.372 0.087 0.365 0.052
3M Mean 387 0.060 2.067 1.417 1.006 2.012 12.775 0.704 3.858 0.297
SD 24 0.007 0.069 0.109 0.074 0.170 1.031 0.093 0.139 0.063
4M Mean 383 0.057 2.075 1.271 1.029 2.098 12.932 0.699 3.532 0.285
SD 29 s0.009 0.092 0.232 0.098 0.223 2.037 0.104 0.558 0.057
Terminal body weight Adrenals Brain Heart Kidneys Liver Ovaries Spleen Thymus Uterus and Cervix
1F Mean 233 0.064 1.935 0.761 1.360 8.305 0.085 0.576 0.279 0.558
SD 17 0.011 0.053 0.062 0.108 0.845 0.023 0.082 0.046 0.196
2F Mean 230 0.063 1.903 0.723 1.317 7.936 0.092 0.571 0.289 0.683
SD 9 0.007 0.086 0.031 0.105 0.570 0.018 0.070 0.063 0.259
3F Mean 229 0.065 1.872 0.757 1.348 8.196 0.086 0.530 0.249 0.512
SD 22 0.010 0.047 0.064 0.087 0.852 0.013 0.123 0.042 0.178
4F Mean 225 0.060 1.909 0.750 1.314 7.567 0.079 0.571 0.295 0.682
SD 17 0.009 0.081 0.132 0.063 0.972 0.013 0.046 0.070 0.200
Fig. 1. Weight gain during 13-week toxicity study in rats.
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(Life Technologies, UK) containing 10% (v/v) heat inactivated fetal calf
serum (HIFCS, Life Technologies, UK) and 0.52% penicillin/strepto-
mycin (Sigma–Aldrich, UK). PHA was included in the culture medium
at a concentration of approximately 2% of culture to stimulate the
lymphocytes to divide. Blood cultures were incubated at 37 ± 1 °C for
48 h and rocked continuously. Immediately prior to treatment, 0.1 mL
culture medium was removed from all continuous cultures to give a
ﬁnal pre-treatment volume of 8.4 mL. In addition, 0.9 mL culture
medium was added to all positive control cultures to give a ﬁnal pre-
treatment volume of 9.3 mL for continuous (24 + 0 h) cultures and
9.4 mL for pulse (3 + 21 h) cultures. S9 mix or KCl (0.5 mL per culture)
was added appropriately. Cultures were treated with the test article or
controls (1 mL per culture or 0.1 mL for positive control cultures).
Cultures were incubated at 37 ± 1 °C for the designated exposure
time. Several drops of suspension were gently spread onto multiple
clean, dry microscope slides and the dried cells were stained for 5 min
using ﬁltered 4% (v/v) Giemsa (pH 6.8). Slides from the highest se-
lected concentration and two lower concentrations were taken for mi-
croscopic analysis, such that a range of cytotoxicity was covered. For
each treatment regime, two vehicle control cultures were analyzed for
micronuclei. Positive control concentrations, which gave satisfactory
responses in terms of quality and quantity of binucleated cells and
numbers of micronuclei, were analyzed. After scoring, slides were de-
coded and the proportion of micronucleated binucleate (MNBN) cells at
each treatment concentration was compared with the concurrent sol-
vent (negative) control using the Fisher's Exact Test (one-sided analysis)
with probability values of p≤ 0.05 accepted as signiﬁcant. A Binomial
dispersion test was conducted to assess homogeneity between replicate
cultures (Richardson et al., 1989) Micronucleus frequency was also
assessed against the historical solvent control (normal) range (95%
reference range, based on percentiles of the observed data (Hayashia
et al., 2011)).
2.4.6. Cytotoxicity test
To evaluate the cytotoxicity of glucuronoxylan hydrolase a Neutral
Red Uptake (NRU) assay in 3T3 cells was performed according to OECD
Guidance Document 129 (OECD, 2010) at Envigo CRS Limited (Cam-
bridgeshire, UK). The growth of 3T3 cells treated with a range of
concentrations of the test item was compared with vehicle control
cultures after 48 h exposure both visually and using neutral red uptake.
2.4.7. Tolerance study in broiler chickens
In order to evaluate the tolerance of broiler chickens to the glu-
curonoxylan hydrolase, a tolerance study was carried out using broilers
chickens in the experimental farm of IRTA in Mas Bover, Spain. The
objective of the trial was to evaluate the dose related eﬃcacy of a
glucuronoxylan hydrolase on performance of broiler chickens and the
tolerance to a high dietary inclusion level. The glucuronoxylan hydro-
lase was evaluated at a maximum recommended dose (11666 GXH(A)/
kg diet) and a ten times overdose (116658 GXH(A)//kg diet) when
added to standard starter, grower and ﬁnisher diets for a period of 6
weeks.
A total of 1920 day-of-hatch broiler chicks (Ross 308), obtained
from a commercial hatchery were kept in a ﬂoor-pen facility and dis-
tributed by sex into 3 treatments allocated in 48 replicate groups of 40
birds each. The birds were fed starter, grower and ﬁnisher diets based
on maize and soybean meal as the main feed ingredients, formulated to
meet the National Research Council (NRC, 1994) nutrient re-
commendations. The composition of the basal diets, as well as the
calculated and the analyzed nutrient contents are summarized in
Table 2. Feeds were given for ad libitum consumption as crumbles in the
starter phase and as 3mm pellets in the grower and ﬁnisher phases. The
quantity of feed required for each dietary treatment was supplemented
on top with the glucuronoxylan hydrolase. The tested glucuronoxylan
hydrolase was analyzed to have a glucuronoxylan hydrolase activity of
69857 GXH(A)/g product.Ta
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The experiment involved 3 dietary treatments as follows: A – ne-
gative control fed non-supplemented basal diets; B – treatment re-
ceiving glucuronoxylan hydrolase at 11666 GXH(A)/kg diet; C –
treatment receiving glucuronoxylan hydrolase at 116658 GXH(A)/kg
diet (overdose). Each dietary treatment was assigned to 16 replicates (8
replicates with male birds and the other 8 with female birds).
Performance parameters monitored during the experimental period
included live weight, live weight gain, feed intake, feed conversion
ratio and mortality.
At the end of the experiment (42 days), blood samples from two
birds per replicate of all treatments (96 samples) were taken for
hematology and biochemical measurements.
Hematological examinations conducted involved the total number
of red blood cells (RBC), blood hemoglobin concentration (HGB), he-
matocrit (HCT), mean corpuscular volume (MCV), mean corpuscular
hemoglobin (MCH), mean corpuscular hemoglobin concentration
(MCHC) and total and diﬀerential number of white blood cells (WBC).
In blood serum the following biochemical parameters were determined:
glucose, bilirubin, cholesterol, uric acid, creatinine, albumin, globulin,
total protein, amylase, creatine kinase, alkaline phosphatase, ALT, AST,
and GGT (gamma glutamyl transferase).
In addition, gross pathology examination was conducted following
blinding procedure on two preselected birds per replicate, to identify
possible changes in peritoneal cavity, lungs, liver, kidney, heart, spleen
and diﬀerent parts of gastro-intestinal tract.
Results were analyzed as a randomized complete block design by
two-way ANOVA. Diﬀerences among treatment means were investigate
by Duncan's multiple range test and were considered signiﬁcant at
P < 0.05.
3. Results & discussion
3.1. Subchronic oral toxicity in rat
The systemic toxic potential of glucuronoxylan hydrolase at doses of
88.9, 293 and 889mg TOS/kg/day was assessed by giving glucur-
onoxylan hydrolase orally by gavage to Wistar rats over a period of 13
Table 6
13-week toxicity study in rats. Clinical Chemistry. Group mean values and standard deviation (in brackets) of males (M) and females (F). Signiﬁcantly diﬀerent from
the controls:*: P < 0.05;**: P < 0.01. Alkaline phosphatase (ALP), Alanine aminotransferase (ALT), Aspartate aminotransferase (AST), Urea, Creatinine (Creat),
Glucose (Gluc), total cholesterol (Chol), Sodium (Na), Potassium (K), Total protein (Total Prot), Albumin (Alb), Albumin/globulin ratio (A/G Ratio).
Group/Sex ALP U/L ALT U/L AST U/L Urea mmol/L Creat μmol/L Gluc mmol/L Chol mmol/L Na mmol/L K mmol/L Total Prot g/L Alb g/L A/G Ratio
1M 83 50 74 7.81 28 9.22 2.38 142 4.3 68 37 1.15
SD 15.0 10.5 19.9 1.752 2.1 0.833 0.384 0.9 0.17 2.1 1.1 0.062
2M 81 49 66 8.12 28 9.18 2.39 142 4.2 66 36 1.18
SD 18.9 8.8 15.2 1.397 3.4 0.760 0.364 0.9 0.22 2.3 1.3 0.070
3M 77 55 81 7.79 28 9.04 2.29 142 4.2 67 37 1.23
SD 13.0 7.1 19.7 0.826 2.7 0.927 0.349 1.0 0.23 2.1 0.9 0.078
4M 74 53 82 7.56 28 8.65 2.38 142 4.1 68 37 1.17
SD 22.0 11.6 26.5 1.333 2.6 1.101 0.413 1.1 0.19 2.6 1.2 0.054
1F 35 51 82 7.45 29 7.98 2.19 143 3.9 73 42 1.41
9.1 15.1 32.0 0.495 4.9 1.399 0.554 1.3 0.15 4.4 2.6 0.110
2F 32 43 71 7.74 33 8.84 1.97 142 4.0 70 42 1.45
SD 6.3 12.0 30.3 0.835 4.3 1.090 0.386 0.9 0.28 3.2 1.8 0.086
3F 33 48 67 8.50 32 8.90 2.12 142 3.8 70 42 1.48
SD 9.2 9.7 11.2 1.035 3.3 0.956 0.452 1.3 0.27 2.5 2.0 0.123
4F 33 36** 59* 7.67 32 8.75 2.11 143 3.8 72 42 1.42
SD 8.5 6.4 7.7 0.693 3.0 0.589 0.475 1.8 0.30 2.8 1.6 0.081
Table 7
In Vitro Cytotoxicity Test: Neutral Red Uptake in BALB/c 3T3 Cell Culture. The
viability of the cells is reported over a range of concentrations of glucuronox-
ylan hydrolase and sodium lauryl sulphate (positive control).
glucuronoxylan hydrolase (mg/mL) Viability (%) SLS (μg/mL) Viability
0 100 0 100
0.01 84 30 124
0.03 88 60 135
0.1 87 75 123
0.3 89 90 90
1 96 95 59
3 78 100 40
10 73 110 13
30 19 120 10
Table 8
Ex vivo/in vitro eye irritation test using Isolated Chicken Eye Test.
Test material Swelling % Opacity Fluorescein retention Irritation categoriesa Irritation Indexb Classiﬁcations (EU-CLPc/UN-GHSd)
glucuronoxylan hydrolase 2 0.8 0.5 I; II; I 28 NC/NC
Bac 5% 38 3.0 3.0e IV; IV; IV 158 1/1
a I= no eﬀect; II = slight eﬀect; III=moderate eﬀect; IV= severe eﬀect.
b Irritation Index = maximum mean corneal swelling + maximum mean opacity (x 20) + mean ﬂuorescein score (x 20).
c EU-CLP: NC=not classiﬁed; Category 2= Irritating to eyes; Category 1= irreversible eﬀects on the eye/serious damage to the eye. Regulation (EC) No 1272/
2808 of the European Parliament and of the Council of 16 December 2008 on classiﬁcation, labelling and packaging of substances and mixtures, amending and
repealing Directives 67/548/EEC and 1999/45/EC, and amending Regulation (EC) No 1907/2806.
d UN-GHS: NC=not classiﬁed; Category 2B=mild irritant, causes eye irritation; Category 2A= irritant, causes eye irritation; Category 1= irreversible eﬀects
on the eye/serious damage to the eye. United Nations-Economic Commission for Europe (UN/ECE) (2003). Globally Harmonised System of Classiﬁcation and
Labelling of Chemicals (GHS). UN, New York and Geneva, 2007.
e Severe loosening of epithelium.
R. Aureli et al. Regulatory Toxicology and Pharmacology 99 (2018) 213–224
219
weeks. Analysis of total nitrogen content, N-total % was performed on
three occasions during the study and showed that all animals had been
adequately exposed to glucuronoxylan hydrolase at increasing doses.
Clinical observations were performed continuously and no adverse
signs of toxicity, ophthalmoscopy, and changes in the appearance or
general behavior were observed that could be attributed to the treat-
ment. There was a non-statistically signiﬁcant trend towards slightly
low body weight gain, when compared with controls, in males receiving
33 or 100% glucuronoxylan hydrolase and a similar trend for food in-
take (Table 3 and Fig. 1); however, this represented trends that were
present before treatment commenced and was therefore not attribu-
table to treatment.
The animals were subjected to a macroscopic necropsy. Speciﬁed
organs and tissues were weighed, ﬁxed and prepared for histopatho-
logical examination. The microscopic examination performed after 13
weeks of treatment revealed no test item related ﬁndings. The incidence
and distribution of all ﬁndings were unrelated to treatment.
All intergroup organ weight diﬀerences were minor, not dose re-
lated, or were the result of single animals aﬀecting the group mean
value (Table 4). Although not statistically signiﬁcant, there was an in-
crease in kidney weight and a reduction of thymus weight in high dose
males but neither ﬁnding was associated with any histopathological
lesions in these tissues. Consequently, these trends were attributed to
normal biological variation and were of no toxicological signiﬁcance.
The hematological investigation in week 13 did not identify any
toxicological signiﬁcant diﬀerences from control. All inter-group dif-
ferences from control, including those attaining statistical signiﬁcance,
were minor, lacked dose-relationship or were conﬁned to one sex and
were therefore attributed to normal biological variation (Table 5).
The biochemical analyses of plasma performed after 13 weeks of
treatment did not reveal any changes in response to treatment with
glucuronoxylan hydrolase. All inter-group diﬀerences from control,
including those attaining statistical signiﬁcance, were minor, lacked
dose-relationship or were conﬁned to one sex and were therefore at-
tributed to normal biological variation (Table 6). In the treated females,
there was a tendency towards slightly low alanine and aspartate amino-
transferase activity, with statistical signiﬁcance being attained at the
high dose. Such trends of decreased plasma activities for these enzymes
are only considered of toxicological importance if there is marked he-
patotoxicity aﬀecting enzyme synthesis in the hepatocytes and there
was clearly no evidence for this from the histopathological investiga-
tion.
3.2. Cytotoxicity test
The growth of 3T3 cells treated with a range of concentrations of the
test item was compared with vehicle control cultures after 48 h ex-
posure both visually and using neutral red uptake.
Glucuronoxylan hydrolase demonstrated cytotoxicity compared to
the vehicle control at the highest concentration of 30mg/mL, slight
cytotoxicity at concentrations 10–3mg/mL and no cytotoxicity ob-
served at the lower concentrations of 1–0.01mg/mL. The estimated
IC50 for glucuronoxylan hydrolase in the present assay was between 10
and 30mg/mL (Table 7).
3.3. Skin and eye irritation
3.3.1. In vitro isolated chicken eye test
Microscopic examination of the corneas generally revealed very
slight erosion and very slight vacuolation of the epithelium after ex-
posure to glucuronoxylan hydrolase. The negative control eye did not
show any corneal eﬀect and demonstrated that the general conditions
during the tests were adequate. Microscopic examination of the cornea
did not reveal any abnormalities, apart from very slight vacuolation of
the epithelium. Without any other eﬀects observed in the cornea, the
very slight vacuolation was considered a chance ﬁnding. The positive
control BAC 5% caused severe corneal eﬀects and demonstrated the ICE
test validity to detect severe eye irritants (Table 8). Applying the clas-
siﬁcation criteria of the ICE, the classiﬁcations as “Not Classiﬁed” (UN-
Table 9
Skin irritation. OD570 of readings and calculated viability (average and stan-
dard deviation (SD)).
Group substance OD570 ± SD (%) Viability± SD (%)
Test Group glucuronoxylan
hydrolase
1.619 ± 0.073 100 ± 5
Negative
control
PBS 1.613 ± 0.090 100 ± 6
Positive
control
5% SDS 0.040 ± 0.001 2 ± 0
Table 10
Bacterial reverse mutation assay; data from experiment 2 only. Mean number of revertant colonies per plate. Abbreviations; TOS:Total Organic Solids. 4-NQO:4-
Nitroquinoline 1-oxide. NaN3:Sodium azide. 2-NF: 2-Nitroﬂuorene. ICR-191:Acridine Mutagen. 2-AA:2-Aminoanthracene.
Compound μg/plate S9 TA98 TA100 TA1535 TA1537 WP2 uvrA pKM101
Puriﬁed water – – 14.3 66.0 30.0 24.0 112.0
glucuronoxylan hydrolase 160 – 20.3 82.0 21.3 6.3 112.7
glucuronoxylan hydrolase 300 – 14.3 78.0 19.0 6.7 137.0
glucuronoxylan hydrolase 625 – 15.3 76.7 16.5 5.3 112.3
glucuronoxylan hydrolase 1250 – 17.7 84.7 16.7 6.7 141.0
glucuronoxylan hydrolase 2500 – 18.0 79.0 15.3 3.3 126.3
glucuronoxylan hydrolase 5000 – 18.0 100.3 27.7 14.7 125.7
2NF 25 – 1496.3
NQO 1 – 601.3
MNNG 2.5 – 1486.0
ICR-191 1 – 1310.7
MNNG 7.5 – 530.3
Puriﬁed water – + 11.0 87.7 22.0 3.3 110.3
glucuronoxylan hydrolase 160 + 12.3 66.0 16.0 6.7 136.7
glucuronoxylan hydrolase 300 + 13.7 72.0 23.0 10.3 145.3
glucuronoxylan hydrolase 625 + 14.3 80.7 25.3 6.3 131.0
glucuronoxylan hydrolase 1250 + 21.7 84.3 24.0 4.7 189.7
glucuronoxylan hydrolase 2500 + 17.7 81.7 23.7 6.7 161.0
glucuronoxylan hydrolase 5000 + 16.0 84.3 25.0 5.7 145.3
AAN 2.5 + 860.3 546.0 44.7
AAN 5 + 97.7
AAN 20 + 278.7
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GHS and EU-CLP classiﬁcations) can be applied.
3.3.2. In vitro skin irritation test using EpiDerm™ reconstructed skin
membranes
The cell viability after glucuronoxylan hydrolase treatment was
found to be 100% with a standard deviation of 5% (Table 9). The ne-
gative control (PBS) was found to be 100% viable with a standard de-
viation of 6% whereas the positive control (SDS) induced a mean via-
bility of 2% with a standard deviation of 0%. A test article is considered
not to possess irritating properties if the cell viability is above 50%,
hence the data of the present study indicate that the glucuronoxylan
hydrolase is a non-irritant (UN GHS No Category).
3.4. Bacterial reverse mutation assay
The results of the bacterial reverse mutation assay (Ames test) are
presented in Table 10. The positive control substances induced sig-
niﬁcant increases in revertant colony numbers, thereby demonstrating
the sensitivity of the bacterial strains and the metabolizing potential of
the S9 mix. No concentration-related and reproducible increases in
revertant colonies were obtained with any of the bacterial strains ex-
posed to glucuronoxylan hydrolase, either in the presence or absence of
S9 mix. Glucuronoxylan hydrolase concentrations up to 5000 μg TOS/
mL were tested. This is the recommended maximum concentration in
current regulatory guidelines. Based on the present data, it is concluded
that glucuronoxylan hydrolase is not mutagenic in the Ames test.
3.5. In vitro micronucleus test in cultured human lymphocytes
Micronuclei were analyzed at four concentrations and a summary of
the data is presented in Table 11. Appropriate negative (vehicle) control
cultures were included in the test system under each treatment condi-
tion. The proportion of micronucleated binucleate (MNBN) cells in
these cultures fell within the current 95th percentile of the observed
historical vehicle control (normal) ranges. Mitomycin C (MMC) and
Vinblastine (VIN) were employed as clastogenic and aneugenic positive
control chemicals respectively in the absence of rat liver S-9. Cyclo-
phosphamide (CPA) was employed as a clastogenic positive control
chemical in the presence of rat liver S-9. Cells were sampled in the
Micronucleus Experiment at 24 h (CPA, MMC) or 48 h (VIN) after the
start of treatment. All positive control compounds induced statistically
signiﬁcant increases in the proportion of cells with micronuclei.
Pulse 3 + 21 h treatment of cells with glucuronoxylan hydrolase, in
the absence and presence of S-9 resulted in frequencies of MNBN cells
which were similar to and not signiﬁcantly (p ≤ 0.05) higher than
those observed in concurrent vehicle controls for all concentrations
analyzed (both treatments). The MNBN cell frequency of all glucur-
onoxylan hydrolase treated cultures (all concentrations) fell within the
95th percentile of the normal ranges.
Following extended (24 + 24 h) treatment in the absence of S-9,
weak increases in MNBN cells were observed at the low concentration
(100 μg TOS/mL, inducing 21% cytotoxicity) and an intermediate
concentration (3000 μg TOS/mL, inducing 43% cytotoxicity). However,
these increases were small and the values of both replicate cultures at
each of these concentrations fell within normal values. No increases
were observed at the highest concentration (4000 μg TOS/mL) or at the
intermediate concentration (1000 μg TOS/mL). The MNBN cell fre-
quencies of all glucuronoxylan hydrolase treated cultures (all con-
centrations) fell within normal ranges. It was therefore considered that
the observed statistical increases were of no biological importance.
It is concluded that glucuronoxylan hydrolase did not induce bio-
logically relevant increases in micronuclei in cultured human periph-
eral blood lymphocytes following treatment in the absence and pre-
sence of S-9. Concentrations were either tested up to the regulatory
recommended maximum of 5000 μg TOS/mL (3 + 21-h treatments), or
were limited by the presence of post treatment precipitate to 4000 μg
TOS/mL (24 h treatment).
3.6. Tolerance study in broiler chickens
Results of the tolerance study are summarized in Table 12. Perfor-
mance of birds in this study was considered normal, as the body weight
of the broiler chickens was close to the standard for the breed in all
periods. During the starter and the grower periods, there was an im-
provement of the feed to gain ratio (FCR) of the broiler chickens re-
ceiving the diet supplemented with the 10 times the recommended dose
when compared to the control diet. The improvement of the FCR was a
combination of numerical eﬀects on weight gain and feed consumption,
suggesting greater availability of the nutrients as a result of enzyme
supplementation. Performance in the overall study showed a signiﬁcant
Table 11
In vitro micronucleus test in cultured human lymphocytes.
Treatment Concentration (μg/mL) Cytotoxicity (%) c Mean MNBN Cell Frequency (%) Historical Control Range (%)b Statistical Signiﬁcance
3 + 21 h -S-9 Vehiclea – 0.30 0.20–1.00 –
1000 10 0.65 NS
3000 10 0.65 NS
4000 19 0.65 NS
5000 34 0.40 NS
MMC, 0.20 34 4.35 p≤ 0.001
3 + 21 h + S-9 Vehiclea – 0.55 0.20–1.07 –
1000 2 0.65 NS
3000 16 0.40 NS
4000 13 0.45 NS
5000 23 0.45 NS
CPA, 3.00 34 1.65 p≤ 0.001
24 + 24 h -S-9 Vehiclea – 0.18 0.10 to 0.90 –
100.0 21 0.45 p≤ 0.05
1000 37 0.30 NS
3000 43 0.75 p≤ 0.001
4000 34 0.40 NS
VIN, 0.04 32 6.80 p≤ 0.001
∗Positive control.
NS Not signiﬁcant.
a Vehicle control was puriﬁed water.
b 95th percentile of the observed range.
c Based on replication index.
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sex*treatment interaction for the FCR indicating that the females re-
ceiving the recommended dose of the enzyme preparation showed a
signiﬁcant improvement (2.1%) in this variable compared to the con-
trol group.
No clinical signs of any health problems were noted during this
study. Mortalities were low across treatments and were not related to
treatments as the level of mortality for the highest inclusion level of
glucuronoxylan hydrolase was similar to that of the control group.
The results of blood hematology did not reveal any relevant changes
due to the dietary administration of the glucuronoxylan hydrolase.
There were no signiﬁcant diﬀerences among the treatments for any of
the variables examined. At the highest inclusion level of the glucur-
onoxylan hydrolase, an increase of mean corpuscular hemoglobin
concentration (MCHC) and a decrease of mean corpuscular volume
(MCV) was noticed, but they were not statistically diﬀerent from the
low dose and the control group. An increase of MCHC leads usually to
an elevated content of hemoglobin which was not the case in this ex-
periment. However, the values for the investigated parameters were
near to the reference values found in the literature (Bounous and
Stedman, 2000; Trîncă et al., 2012). The proportion of heterophils,
eosinophils, basophils, lymphocytes and monocytes recorded in the
study were close to the reference values (Hoﬀmann, 1961). Those he-
matology ﬁndings were not consistent with a treatment-related eﬀect,
and in the absence of a decreased hemoglobin concentration in the
plasma of the treated groups, no anemia and safety concern could be
reported with increasing inclusion level of the glucuronoxylan hydro-
lase.
The blood chemical analyses showed no signiﬁcant diﬀerences
among the treatments for any of the variables examined, except for
creatine which was higher in the control group than in the treatments
supplemented with the enzyme, although diﬀerences were very small. A
signiﬁcant reduction of creatine kinase activity was recorded in the
broiler chickens receiving the ten times recommended dose.
A general necropsy was performed where special attention was
drawn to the kidney, the liver, the spleen, the lungs and the heart. The
avian necropsy did not show any adverse eﬀects associated with the
dietary treatments.
According to the results recorded in this study, the glucuronoxylan
hydrolase was well tolerated even at ten times the maximum re-
commended dose.
4. Conclusion
The present work describes the methodologies and results of several
toxicological studies performed to evaluate the safety of the novel mi-
crobial glucuronoxylan hydrolase as feed additive as well as the
Table 12
Eﬀects of the glucuronoxylan hydrolase supplementation on broiler performance and selected hematological and blood biochemical parameters.
Parameter A B C
Control glucuronoxylan hydrolase (11666 GXH(A)/kg) glucuronoxylan hydrolase (116658 GXH(A)/kg)
Performance parameters (male + female)
Starter
Final weight, day 0–14 478 473 482
Feed/gain ratio, day 0–14 1.164a 1.155a 1.142b
Grower
Final weight, day 14–28 1489 1476 1504
Feed/gain ratio, day 14–28 1.502a 1.488ab 1.474b
Finisher
Final weight, day 28–42 2838 2801 2822
Feed/gain ratio, day 28–42 1.748 1.728 1.76
Overall
Final weight, day 0–42 2838 2801 2822
Feed/gain ratio, day 0–42 1.565 1.550 1.555
Heamatological parameters
Red blood cells (x106/μL) 2.46E+06 2.41E+06 2.46E+06
Hemoglobin (g/100mL) 12 12 12
Hematocrit (%) 30.8 30.3 30.3
Mean corpuscular volume (ﬂ) 126 126 123
Mean corpuscular hemoglobin (pg/L) 48.4 49 48.5
Mean corpuscular hemoglobin concentration 38.7 38.9 39.4
Eosinophils (% WBC) 9.83 8.24 8.35
Basophils (% WBC) 3.10 4.00 3.10
Lymphocytes (% WBC) 35.5 38.9 39.5
Monocytes (% WBC) 4.17 5.31 3.32
Heterophils (% WBC) 47.4 43.5 45.7
Blood biochemical parameters
Glucose (mg/dL) 231 232 225
Bilirubin (mg/dL) 0.115 0.113 0.118
Cholesterol (mg/dL) 140 139 142
Uric acid (mg/dL) 5.8 5.3 5.2
Creatinine (mg/dL) 0.23a 0.22b 0.22b
Albumin (g/L) 11 11 11
Globulin (g/L) 20 20 20
Total protein (g/L) 32 31 31
Amylase (U/L) 500 446 481
Alkaline phosphatase (U/L) 5336 5719 5460
Creatine phosphokinase (U/L) 48887a 43841ab 34526b
ALT (U/L) 2.9 2.9 2.7
AST(U/L) 507 502 432
GGT (U/L) 19 17 20
a,b Means within the same row without a common letter are signiﬁcantly diﬀerent (P < 0.05).
Mean of 8 replicates of males or 8 replicates of females.
Means followed by diﬀerent letters are signiﬁcantly diﬀerent, Duncan's multiple range test, P < 0.05.
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tolerance study of the novel enzyme in broiler chickens. The protocols
for the studies were selected to meet, at least, the regulatory require-
ments applicable for a feed enzyme in Europe.
The 6-week tolerance study conﬁrmed that the glucuronoxylan
hydrolase is safe for broiler chickens when fed at the maximum re-
commended dose, as well as at the 10 times higher dose. The results did
not reveal any signiﬁcant changes due to dietary administration of the
glucuronoxylan hydrolase in terms of hematological and biochemical
examinations and post mortem necropsy.
A toxicological evaluation of the glucuronoxylan hydrolase as pre-
scribed by the European Food Safety Authority (EFSA, 2012) was car-
ried out. The studies were performed at the highest dose levels required
by the current OECD guidelines. Glucuronoxylan hydrolase adminis-
tered by oral gavage to rats for 13 weeks did not cause any adverse
eﬀect. In addition, glucuronoxylan hydrolase did not exhibit irritative
potential when applied to the eye using the in vitro isolated chicken eye
test or to the skin using the in vitro three-dimensional EpiDerm™ model.
Finally, glucuronoxylan hydrolase was found not to represent muta-
genic or clastogenic potential when tested in relevant genotoxicological
assays. Acute aquatic toxicity evaluated with daphnia and algae, com-
bined with the biodegradability of xylanase enzymes in general shows a
low safety concern for the aquatic environment (REACH dossier 01-
2120747946-38-0000). Based on the tolerance trial in broilers, the
toxicological data and the fact that the Bacillus licheniformis production
organism derives from a safe strain lineage, it is concluded that there
are no reasons for safety concerns when using this glucuronoxylan
hydrolase as a feed additive.
In conclusion, glucuronoxylan hydrolase is an advantageous ad-
ditive to chicken feed and cause no harm to the environment. The po-
sitive safety evaluation of glucuronoxylan hydrolase is in line with the
fact that this type of enzyme is ubiquitous in nature. However, from a
workers’ safety perspective, glucuronoxylan hydrolase should, like any
other enzyme, be handled according to the standard safety guidelines
for enzymes to avoid respiratory sensitization.
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